Menopausal Population Growth Fuels Expansion Of Vasomotor Menopausal Symptoms Treatment Market Driver: Leading Transformation in the Vasomotor Menopausal Symptoms (VMS) Treatment Market in 2025

Which drivers are expected to have the greatest impact on the over the vasomotor menopausal symptoms (vms) treatment market's growth?
The rise in the population of menopausal women is predicted to drive the vasomotor menopausal symptom's treatment market expansion. Menopause, a natural system marking the conclusion of reproductive years in a woman, typically takes place between the ages of 45 and 55, with the average age being roughly 51. The increase in the number of women reaching menopause and seeking treatments for symptoms like hot flashes and vaginal dryness is a major catalyst for the vasomotor menopausal symptoms (VMS) treatment market's growth. As an illustration, the Cuyuna Regional Medical Center, a US-based institution, projected in November 2022 that the menopausal women population will reach 1.1 billion by 2025 due to increased life expectancy, and will continue to grow by 1.6% per year until 2060. Therefore, the upsurge in menopausal women is a key contributor to the growth of the vasomotor menopausal symptom's treatment market. Driver: Government's Drive for Women's Health in Menopause Enhances Growth of Vasomotor Menopausal Symptom Treatment Market

Get Your Vasomotor Menopausal Symptoms (VMS) Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

What is the future CAGR of the vasomotor menopausal symptoms (vms) treatment market, and how will it impact industry expansion?
The market size for treating vasomotor menopausal symptoms (VMS) has seen robust growth in recent years. The market, which is anticipated to rise from $17.86 billion in 2024 to $19.19 billion in 2025, will witness an annual compounded growth rate (CAGR) of 7.5%. Factors such as hormone replacement therapy (hrt), increased awareness about menopause, advances in pharmaceutical treatments, and consumer demand are responsible for the growth during the historic period.

The market for treatment of vasomotor menopausal symptoms (VMS) is poised to witness robust expansion in the forthcoming years. The market size is predicted to escalate to $24.81 billion by 2029, registering a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this growth during the projected span include advancements in personal medicine, non-hormonal alternatives, improvements in nutrition and dietary regimes, along with the integration of telemedicine and digital health. Key tendencies observed during the forecast tenure are the adoption of natural and alternative treatments, usage of botanical and herbal remedies, proliferation of menopause support groups, and the implementation of cognitive behavioral therapy (cbt).

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

What are the most significant trends transforming the vasomotor menopausal symptoms (vms) treatment market today?
Leading firms in the treatment sector for vasomotor menopausal symptoms are manufacturing products like Veozah and earning approval to offer alternative treatment choices to fulfil the unmet healthcare needs of patients. The authorization of new medications for menopause adds to the effectiveness and safety compared to the present treatment methods. Astellas Pharma Inc, a Japan-headquartered pharmaceutical corporation, for instance, garnered approval for Veozah (fezolinetant) 45 mg daily dosage from the US-based Food and Drug Administration (FDA) in May 2023, for the treatment of vasomotor symptoms (VMS) related to menopause, varying from mild to severe levels. This is the inaugural nonhormonal neurokinin 3 (NK3) receptor antagonist cleared for the treatment of menopause-related VMS. Veozah is a hormone-free choice that obstructs a pathway within the brain. This controls these symptoms and provides women an alternative treatment technique, especially for those unable or unwilling to use hormone therapy. The sanctioning of Veozah underscores its potential as a novel medication for managing menopausal symptoms.

Which key market segments comprise the vasomotor menopausal symptoms (vms) treatment market and drive its revenue growth?
The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented -

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the leading players fueling growth in the vasomotor menopausal symptoms (vms) treatment market?
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp

What Is Covered In The Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report?

•Market Size Forecast: Examine the vasomotor menopausal symptoms (vms) treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the vasomotor menopausal symptoms (vms) treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the vasomotor menopausal symptoms (vms) treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the vasomotor menopausal symptoms (vms) treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the vasomotor menopausal symptoms (vms) treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the vasomotor menopausal symptoms (vms) treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the vasomotor menopausal symptoms (vms) treatment market.
•Competitive Landscape: Review strategic developments in the vasomotor menopausal symptoms (vms) treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.